Chronic myelogenous leukemia (CML) is a pluripotential hematopoietic stem cell malignancy characterized by three distinct phases: chronic, accelerated, and blast crisis phases. It is classified as a myeloproliferative disorder and accounts for 15% of adult leukemia cases.
A myeloproliferative neoplasm characterized by the presence of Philadelphia chromosome and that involves the myeloid, erythroid, megakaryocytic, and occasionally lymphoid bloodlines.
CML is diagnosed by identification of the Philadelphia chromosome in either peripheral blood or bone marrow aspirate.
The Philadelphia chromosome consist of a chromosomal translocation T (9; 22) (q34; q11), that results from fusion of the gene BCR ABL1.
Cytogenetic analysis consist of conventional chromosomal analysis of 20 metaphases as well as fluorescence in situ hybridization and polymerase chain reaction for BCR: ABL1 transcripts in either peripheral blood or bone marrow aspirate..
Epidemiology and Incidence Current Statistics
Annual incidence: Approximately 1-2 cases per 100,000 population.
Lifetime risk: Approximately 1 in 526 in the US
2023 estimates: 8,930 new diagnoses, 1,310 deaths.
In 2024 approximately 9300 cases were diagnosed.
Currently 4 to 5,000,000 people have CML and it’s estimated that more than 10 million individuals will be living with CML in 2040-2050.
Adult leukemia proportion: 14% of all new leukemias, 20% of adult leukemias
Pediatric cases: Exceedingly rare, accounts for 2-3% of childhood leukemias
Demographics
Median age at presentation: 50-60 years (some sources indicate 67 years).
Age distribution: 12-30% of patients are >60 years at diagnosis.
Gender/ethnic factors: No known hereditary, familial, geographic, or ethnic associations
Prognosis and Survival Pre-TKI mortality: 10% in first two years, 20-25% in subsequent years.
Modern 10-year survival: >90% for newly diagnosed CML
Current mortality rate: ~2% per year for first 10 years
Life expectancy: Approaching that of healthy population with TKI treatment
Pathophysiology
Molecular Basis
Primary genetic abnormality: Philadelphia chromosome – t(9;22)(q34;q11) present in 95% of cases
Molecular mechanism:
Reciprocal translocation between chromosomes 9 and 22
Fusion of BCR gene (chromosome 22) with ABL1 gene (chromosome 9)
Creates BCR-ABL fusion gene encoding p210(BCR-ABL) protein
Results in constitutively active tyrosine kinase enzyme
Leads to deregulated cellular proliferation and unlimited self-renewal
Activation by the BCR: ABL1, oncoene of pathways involving mitogen activated protein kinase, MYC, RAS, STAT, and PI3K.
Transcript Types b3a2 transcript: Predominant type
e14a2 (BCR-ABL1): Associated with earlier response and better outcomes with imatinib
e13a2: Associated with poorer clinical outcomes than e14a2
Cryptic Cases 5-10% of cases have cytogenetically cryptic Philadelphia chromosome, requiring: Fluorescence in situ hybridization (FISH) for BCR-ABL fusion detection Polymerase chain reaction (PCR) for BCR-ABL mRNA transcript detection
Risk Factors
Environmental Increased incidence in atomic bomb survivors (Japan) Radiation exposure (radiologists, ankylosing spondylitis patients treated with radiation)
Genetic Markers Der(9) deletions: Present in 10-15% of patients, associated with unfavorable prognosis More common in younger patients and those with anemia
Clinical Presentation Disease Phases Chronic Phase (85% of presentations) Duration: Usually lasts 3-5 years, may extend to 4-6 years Symptoms: Up to 50% are asymptomatic at diagnosis Bone marrow blasts: <15% Peripheral blood blasts: <15%
Accelerated Phase (15% progression rate) Duration: May last up to 1 year Criteria (one or more): 15% or more blasts in peripheral blood/bone marrow 20% or more basophils in peripheral blood Platelet count <100,000/μL (unrelated to treatment) Cytogenetic evolutionBone marrow/peripheral blasts: 15-30%
Blast Crisis Phase Duration: 3-6 months Definition: >30% blasts in bone marrow or peripheral blood Types: Myeloid (2/3 of cases) Lymphoid (1/3 of cases)
Features: Acute leukemia symptoms (fever, weight loss, bleeding, anemia)
Clinical Signs and Symptoms Common Presentations Splenomegaly: Present in 46-76% of patients Left upper quadrant pain: Due to splenomegaly Early satiety: Related to spleen enlargement Constitutional symptoms: Night sweats, fatigue Anemia symptoms: Weakness, shortness of breath Bleeding: Due to platelet dysfunction
Rare Presentations Hyperviscosity symptoms: <5% of patients when WBC >250,000/μLPriapism: When white count exceeds 250,000/μL
Laboratory Findings Characteristic Hematologic Pattern Absolute leukocytosis with left shift Classic “myelocyte bulge” Blast count: Usually <2% in chronic phase Basophilia: Nearly universal Absolute eosinophilia: 90% of cases Monocytosis: Present but not increased percentage Platelet count: Normal to elevated; thrombocytopenia possible
Differential Diagnosis Chronic myelomonocytic leukemia Atypical CML Chronic neutrophilic leukemia
Essential thrombocytosis
Diagnostic Workup
History and physical examination Spleen palpation
Complete blood count with differential
Comprehensive metabolic panel
Hepatitis B panel
Definitive Diagnosis: Bone marrow aspirate and biopsy: Morphologic evaluation Cytogenetic analysis Flow cytometry Molecular studies: Quantitative RT-PCR for BCR-ABL1 transcript FISH for t(9;22)(q34;q11.2) Baseline BCR-ABL1 quantification for monitoring
Risk Stratification Chronic phase CML risk groups: Low, intermediate, and high Risk factors: Patient age Spleen size Platelet count Percentage of blasts, basophils, and eosinophils in peripheral blood
Prognostic associations: Higher age → increased mortality risk Higher peripheral blasts → increased mortality risk Larger spleen → increased mortality risk Low platelet counts → increased mortality risk
Treatment Overview
Primary Goals Complete hematologic response at 3 months Complete cytogenetic response at 12 months Major molecular response at 18 months
Response Definitions Hematologic Response: Normalization of WBC count Resolution of splenomegaly
Cytogenetic Response: Complete (CCyR): 0% Philadelphia+ metaphases Major: 0-35% Philadelphia+ metaphasesMinor: 35-90% Philadelphia+ metaphases
Molecular Response: Major Molecular Response (MMR): BCR-ABL ≤0.1% (3-log reduction) Deep Molecular Responses (DMR): MR4.0: BCR-ABL <0.01% MR4.5: BCR-ABL <0.0032% MR5: BCR-ABL <0.001% (5-log reduction)
Complete Molecular Response: Undetectable BCR-ABL by PCR
Tyrosine Kinase Inhibitor (TKI) Therapy First-Line TKIs for Chronic Phase Imatinib (Standard of Care) • Dosage: 400 mg daily (standard), 600-800 mg daily (high-dose) • IRIS Trial Results: • Complete cytogenetic response: 87% achieved at some time • 5-year progression-free survival: 83% • 5-year overall survival: 89% • Major molecular response at 12 months: 40% Efficacy Outcomes: • 75% complete cytogenetic remission at 400 mg/day • 90% complete cytogenetic remission at 800 mg/day • Overall survival at 8 years: 86%
Second-Generation TKIs Dasatinib: • Dosage: 100 mg once daily • Advantages: Faster time to major molecular response (6.3 vs 9.2 months vs imatinib) • Response rates: 45% MMR vs 28% with imatinib • Complete cytogenetic response: 77% vs 66% with imatinib
Nilotinib: • Dosage: 300 mg twice daily • ENESTnd Trial: Superior to imatinib for MMR (44% vs 22%) and CCyR (79% vs 65%) • Characteristics: More potent and selective than imatinib
Bosutinib: • BEFORE Study: Higher 12-month MMR than imatinib • Side effects: Higher GI events and transaminase elevations Third-Generation TKIs
Ponatinib (Iclusig): • Indication: Resistant/intolerant to prior TKI therapy • Special feature: Active against T315I mutation • Target population: T315I-positive patients
Asciminib: • Generation: Third-generation TKI • Indication: Effective in relapsed disease • Mechanism: BCR-ABL1 inhibitor with superior efficacy and favorable safety profile
TKI Selection Guidelines First-Line Selection Criteria • Low-risk patients: Generic imatinib recommended • Intermediate/high-risk patients: Dasatinib or nilotinib preferred • Young patients: Consider second-generation TKIs for higher chance of deep molecular response Comorbidity Considerations • Heart disease/arrhythmias/pancreatitis/hyperglycemia: Prefer dasatinib • Lung disease/pleural effusion risk: Prefer nilotinib Resistance and Mutations BCR-ABL Mutations • Frequency: Account for 36-48% of imatinib-resistant cases • Most common mechanism of imatinib resistance • Can occur: Before or after treatment initiation T315I “Gatekeeper” Mutation • Frequency: 5-25% of patients (higher in relapsed disease) • Resistance profile: All first and second-generation TKIs • Molecular change: Isoleucine substitution for threonine at position 315 • Treatment: Ponatinib is active against T315I Management of Resistance • Dose escalation: Imatinib 800 mg daily can overcome some resistance • TKI switching: Second-generation TKIs for imatinib failure • Mutation testing: Guide TKI selection • Omacetaxine: Can overcome T315I mutation Treatment Monitoring and Response Assessment Monitoring Schedule Methods: Hematologic, cytogenetic, and molecular assessments Early Response Predictors • 3-month BCR-ABL levels: • <10% (1-log reduction): Associated with improved long-term outcomes • 1-2 log reduction: 69% achieve MMR • 2-log reduction: 100% achieve MMR • ≤1-log reduction: Only 13% achieve MMR Response Kinetics and Outcomes • Speed of response: Critical for long-term success • Early CCyR: Associated with better overall survival • MMR by 12 months: 91% event-free survival vs 78% without MMR • Deep molecular responses: Correlated with survival and treatment discontinuation eligibility Treatment-Free Remission (TFR) Rationale • Reduce TKI-related adverse events • Minimize pharmacologic and economic burden • Prevent long-term toxicities Eligibility Criteria • Sustained deep molecular response: Usually MR4.5 for ≥2 years • Treatment duration: Minimum 3 years of TKI therapy • Risk assessment: Not recommended for higher-risk patients TFR Study Results STIM Study • Participants: 100 patients with sustained complete molecular response (>5-log reduction for ≥2 years) • Molecular relapse: 54% after median 17 months • Sustained remission: 46% remained in CMR at median 14 months • 12-month probability: 43% maintained CMR TWISTER Study • Relapse-free interval: 47% at 2 years • Re-treatment sensitivity: All patients responsive to imatinib re-introduction DASFREE Trial (Dasatinib) • 1-year TFR rate: 49% • Molecular relapse: 51% lost MMR after median 4 months • Re-treatment response: All patients regained MMR after median 2 months TFR Outcomes by TKI • Second-generation TKIs: Higher TFR rates than imatinib due to deeper molecular responses • Overall success: ~50% maintain remission at 2 years after stopping first or second-line therapy • Relapse timing: Most relapses occur within 6 months of discontinuation Advanced Phase CML Management Accelerated Phase (CML-AP) • Initial therapy: Newer generation TKIs (dasatinib or ponatinib preferred over imatinib) • Goal: Reduce CML burden • Consideration: Early allogeneic stem cell transplantation Blast Crisis (CML-BP) • Treatment approach: TKI + chemotherapy combinations • Response rates: • Nonlymphoid CML-BP: 40% • Lymphoid CML-BP: 70-80% • Median survival: • Nonlymphoid: 6-12 months • Lymphoid: 12-24 months • Optimal approach: TKI + intensive chemotherapy followed by stem cell transplantation Stem Cell Transplantation Indications • Current role: No longer first-line for chronic phase CML • Preferred candidates: Younger patients with HLA-matched donors • Timing: Within 1 year of diagnosis for optimal outcomes Outcomes • Chronic phase transplant: ~70% survival rate • Young patients (within 1 year): 50-55% 10-year survival • Blast crisis transplant: Only 6% 5-year survival • Long-term outcomes: • 10-year overall survival: 65.7% (with pre-transplant TKI) vs 73.0% (without) • 20-year CML-related mortality: 6% • 20-year non-CML-related mortality: 36% Graft-vs-Tumor Effect • Donor lymphocyte infusions: 60-80% complete remission in relapsed patients • Relapse rate: 10-20% within 3 years post-transplant Pediatric CML Epidemiology • Frequency: Exceedingly rare, 2-3% of childhood leukemias • Treatment: Imatinib effective with response rates similar to adults Response Rates in Children (12 months) • Complete hematologic response: 98% • Complete cytogenetic response: 61% • Major molecular response: 31% Adverse Effects and Safety Profile TKI-Specific Toxicities Imatinib • Common: Superficial edema, nausea, muscle cramps, rashes • Grade 3-4 non-hematologic: Musculoskeletal pain (2.7%), joint pain (2.4%), abdominal pain (2.4%) • Hematologic: Neutropenia (14.3%), thrombocytopenia (7.8%), anemia (3.1%) Second-Generation TKIs • Nilotinib: Vascular events • Dasatinib: Pulmonary hypertension, pleural effusions • Bosutinib: Mild renal effects, GI toxicity Third-Generation TKIs • Ponatinib: Vascular events (arterial thrombosis) Long-Term Considerations • Cardiovascular events: Increased risk with several TKIs • Surveillance: Regular monitoring for cardiovascular complications • Quality of life: Consider in treatment selection and TFR decisions Future Directions and Research Combination Therapies • TKI + Interferon: Better short-term results, no long-term survival benefit • TKI + Chemotherapy: Improved outcomes in blast crisis Novel Approaches • Asciminib: Promising third-generation option • Treatment optimization: Personalized medicine based on risk stratification • TFR expansion: Identifying optimal candidates and timing Biomarkers and Predictors • OCT-1 levels: Predict imatinib response (higher levels = better survival) • BCR-ABL transcript levels: Guide treatment decisions and monitoring • Molecular monitoring: Essential for treatment optimization and TFR decisions Key Clinical Pearls 1. Early response matters: BCR-ABL <10% at 3 months predicts better long-term outcomes 2. Deep molecular responses: Enable treatment discontinuation consideration 3. T315I mutation: Requires ponatinib for effective treatment 4. TFR is achievable: ~50% of selected patients maintain remission off treatment 5. Second-generation TKIs: Faster responses but no clear overall survival advantage over imatinib 6. Modern CML prognosis: Life expectancy approaching normal population 7. Monitoring is crucial: Regular molecular monitoring guides treatment decisions 8. Resistance is manageable: Multiple TKI options available for treatment failure